Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial.

Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, Lee VHF, Ma BBY, Cheng HC, Wong FCS, Loong HHF, Tong M, Poon DMC, Ahuja AT, King AD, Wang K, Mo F, Zee BCY, Chan KCA, Lo YMD.

J Clin Oncol. 2018 Jul 10:JCO2018777847. doi: 10.1200/JCO.2018.77.7847. [Epub ahead of print]

PMID:
29989858
2.

Recommendations on prevention and screening for breast cancer in Hong Kong.

Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R.

Hong Kong Med J. 2018 Jun;24(3):298-306. doi: 10.12809/hkmj177037.

3.

Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma.

Wong CH, Ma BBY, Hui CWC, Lo KW, Hui EP, Chan ATC.

Sci Rep. 2018 May 22;8(1):8010. doi: 10.1038/s41598-018-26201-1.

4.

Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma.

Lam WKJ, Jiang P, Chan KCA, Cheng SH, Zhang H, Peng W, Tse OYO, Tong YK, Gai W, Zee BCY, Ma BBY, Hui EP, Chan ATC, Woo JKS, Chiu RWK, Lo YMD.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5115-E5124. doi: 10.1073/pnas.1804184115. Epub 2018 May 14.

5.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27.

PMID:
29584545
6.

Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.

Ma B, Hui EP, King A, Leung SF, Kam MK, Mo F, Li L, Wang K, Loong H, Wong A, Chan CM, Chan KCA, Wong SCC, Lo YMD, Chan AT.

Br J Cancer. 2018 Apr;118(8):1051-1055. doi: 10.1038/s41416-018-0026-9. Epub 2018 Mar 20.

PMID:
29555989
7.

Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials.

Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM, Chen MY, Ma J.

Clin Cancer Res. 2018 Apr 15;24(8):1824-1833. doi: 10.1158/1078-0432.CCR-17-2656. Epub 2018 Feb 5.

PMID:
29431618
8.

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study.

Hui EP, Ma BBY, Loong HHF, Mo F, Li L, King AD, Wang K, Ahuja AT, Chan CML, Hui CWC, Wong CH, Chan ATC.

Clin Cancer Res. 2018 Mar 1;24(5):1030-1037. doi: 10.1158/1078-0432.CCR-17-1667. Epub 2018 Jan 4.

PMID:
29301831
9.

Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization.

Yu SCH, Chan SL, Lee KF, Hui JWY, Hui EP, Chu CM, Chan AW, Cheung S, Li L, Wong J, Yeo WMM.

Radiology. 2018 Apr;287(1):340-348. doi: 10.1148/radiol.2017170154. Epub 2017 Dec 22.

PMID:
29272212
10.

Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases.

Ai QY, Hu CW, Bhatia KS, Poon DMC, Hui EP, Mo FKF, Law BKH, Tong M, Ma BB, Chan ATC, King AD.

Eur Arch Otorhinolaryngol. 2018 Feb;275(2):497-505. doi: 10.1007/s00405-017-4825-z. Epub 2017 Nov 29.

PMID:
29188437
11.

Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.

Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, Chan G, Hui EP, Ma BBY, Chiu RWK, Leung SF, van Hasselt AC, Chan ATC, Lo YMD.

N Engl J Med. 2017 Aug 10;377(6):513-522. doi: 10.1056/NEJMoa1701717. Erratum in: N Engl J Med. 2018 Mar 8;378(10 ):973.

12.

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.

Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH.

Cancer. 2017 Oct 15;123(20):3977-3985. doi: 10.1002/cncr.30825. Epub 2017 Jun 22.

PMID:
28640364
13.

Investigational drugs for nasopharyngeal carcinoma.

Ma BBY, Hui EP, Chan ATC.

Expert Opin Investig Drugs. 2017 Jun;26(6):677-685. doi: 10.1080/13543784.2017.1324568. Epub 2017 May 8. Review.

PMID:
28446055
14.

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.

Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, Lun SW, Jia L, Chan AW, Chan JY, Lai PB, Fung CY, Hung ST, Wang L, Chang AM, Chiosea SI, Hedberg ML, Tsao SW, van Hasselt AC, Chan AT, Grandis JR, Hammerman PS, Lo KW.

Nat Commun. 2017 Jan 18;8:14121. doi: 10.1038/ncomms14121.

15.

Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.

Li L, Mo FK, Chan SL, Hui EP, Tang NS, Koh J, Leung LK, Poon AN, Hui J, Chu CM, Lee KF, Ma BB, Lai PB, Chan AT, Yu SC, Yeo W.

BMC Cancer. 2017 Jan 4;17(1):8. doi: 10.1186/s12885-016-2995-5.

16.

Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.

Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong Ng W, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lee AW, Blanchard P, Michiels S; MAC-NPC Collaborative Group.

J Natl Cancer Inst. 2017 Apr;109(4). pii: djw239.

17.

Acupuncture and Related Therapies for Symptom Management in Palliative Cancer Care: Systematic Review and Meta-Analysis.

Lau CH, Wu X, Chung VC, Liu X, Hui EP, Cramer H, Lauche R, Wong SY, Lau AY, Sit RS, Ziea ET, Ng BF, Wu JC.

Medicine (Baltimore). 2016 Mar;95(9):e2901. doi: 10.1097/MD.0000000000002901. Review.

18.

Chinese Herbal Medicine for Symptom Management in Cancer Palliative Care: Systematic Review And Meta-analysis.

Chung VC, Wu X, Lu P, Hui EP, Zhang Y, Zhang AL, Lau AY, Zhao J, Fan M, Ziea ET, Ng BF, Wong SY, Wu JC.

Medicine (Baltimore). 2016 Feb;95(7):e2793. doi: 10.1097/MD.0000000000002793. Review.

19.

Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma.

Raghupathy R, Ayyappan S, Prabhakar D, Campagnaro EL, Mo FK, Li W, Hui EP, Chan AT, Lei KI.

Br J Haematol. 2017 Jan;176(2):315-317. doi: 10.1111/bjh.13942. Epub 2016 Jan 26. No abstract available.

PMID:
26814167
20.

Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor Outcomes.

Yu SC, Hui EP, Tang P, Chan SK, Chu CC, Hui JW, Chan SL, Lee KF, Lai PB, Yeo W.

J Vasc Interv Radiol. 2016 May;27(5):639-49. doi: 10.1016/j.jvir.2015.11.032. Epub 2016 Jan 20.

21.

Viral co-infections and paraproteins in HIV: effect on development of hematological malignancies.

Jou E, Gligich O, Chan AC, Mohan D, Felsen UR, Ayyappan S, Billett HH, Hui EP, Chan AT, Raghupathy R.

Ann Hematol. 2016 Mar;95(4):575-80. doi: 10.1007/s00277-016-2588-z. Epub 2016 Jan 9.

22.

Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overview of Systematic Reviews and Network Meta-Analysis.

Wu X, Chung VC, Lu P, Poon SK, Hui EP, Lau AY, Balneaves LG, Wong SY, Wu JC.

Medicine (Baltimore). 2016 Jan;95(1):e2410. doi: 10.1097/MD.0000000000002410. Review.

23.

Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses.

Chung VC, Wu X, Hui EP, Ziea ET, Ng BF, Ho RS, Tsoi KK, Wong SY, Wu JC.

Sci Rep. 2015 Dec 16;5:18111. doi: 10.1038/srep18111. Review.

24.

Effectiveness of acupuncture and related therapies for palliative care of cancer: overview of systematic reviews.

Wu X, Chung VC, Hui EP, Ziea ET, Ng BF, Ho RS, Tsoi KK, Wong SY, Wu JC.

Sci Rep. 2015 Nov 26;5:16776. doi: 10.1038/srep16776. Review.

25.

Nasopharyngeal carcinoma.

Chua MLK, Wee JTS, Hui EP, Chan ATC.

Lancet. 2016 Mar 5;387(10022):1012-1024. doi: 10.1016/S0140-6736(15)00055-0. Epub 2015 Aug 28. Review.

PMID:
26321262
26.

Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients.

Jou E, Gligich O, Chan AC, Mohan D, Felsen UR, Ayyappan S, Billett HH, Hui EP, Chan AT, Raghupathy R.

Hematol Oncol. 2017 Mar;35(1):64-68. doi: 10.1002/hon.2247. Epub 2015 Jul 24.

PMID:
26205037
27.
28.

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

Ma BB, Goh BC, Lim WT, Hui EP, Tan EH, Lopes Gde L, Lo KW, Li L, Loong H, Foster NR, Erlichman C, King AD, Kam MK, Leung SF, Chan KC, Chan AT.

Invest New Drugs. 2015 Aug;33(4):985-91. doi: 10.1007/s10637-015-0264-0. Epub 2015 Jun 19.

PMID:
26084990
29.

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, Chan AW, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SC.

BMC Cancer. 2015 May 12;15:395. doi: 10.1186/s12885-015-1334-6.

30.

Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis.

Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group.

Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.

PMID:
25957714
31.

Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.

Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT.

Cancer. 2015 Aug 15;121(16):2720-9. doi: 10.1002/cncr.29413. Epub 2015 May 6.

32.

Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.

Zheng Y, Parsonage G, Zhuang X, Machado LR, James CH, Salman A, Searle PF, Hui EP, Chan AT, Lee SP.

Cancer Immunol Res. 2015 Oct;3(10):1138-47. doi: 10.1158/2326-6066.CIR-14-0203-T. Epub 2015 Feb 24. Erratum in: Cancer Immunol Res. 2016 Feb;4(2):173-4.

33.

Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.

Sung FL, Cui Y, Hui EP, Li L, Loh TK, Tao Q, Chan AT.

Am J Cancer Res. 2014 Nov 19;4(6):789-800. eCollection 2014.

34.

A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM.

Clin Cancer Res. 2014 Oct 1;20(19):5009-22. doi: 10.1158/1078-0432.CCR-14-1122-T. Epub 2014 Aug 14.

35.

Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic.

Raghupathy R, Hui EP, Chan AT.

Am Soc Clin Oncol Educ Book. 2014:149-53. doi: 10.14694/EdBook_AM.2014.34.149. Review.

36.

Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.

Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC, Leung L, Chu KW, Zee B, Lo YM, Chan AT.

Ann Oncol. 2014 Jun;25(6):1204-8. doi: 10.1093/annonc/mdu117. Epub 2014 Mar 17.

PMID:
24638904
37.

Advanced technologies for studying circulating tumor cells at the protein level.

Chan CM, Au TC, Chan AT, Ma BB, Tsui NB, Ng SS, Hui EP, Chan LW, Ho WS, Yung BY, Wong SC.

Expert Rev Proteomics. 2013 Dec;10(6):579-89. doi: 10.1586/14789450.2013.858021. Review.

PMID:
24206230
38.

Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing.

Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS, Chan HL, Wong CS, Ma BB, Chan AT, Lai PB, Sun H, Chiu RW, Lo YM.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18761-8. doi: 10.1073/pnas.1313995110. Epub 2013 Nov 4.

39.

Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.

Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T, Yeo W.

Radiology. 2014 Feb;270(2):607-20. doi: 10.1148/radiol.13130498. Epub 2013 Oct 28.

PMID:
24126369
40.

Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.

Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray RD, Wong SC, To KF, King AD, Ahuja A, Chan AT.

Cancer. 2013 Dec 1;119(23):4145-53. doi: 10.1002/cncr.28327. Epub 2013 Oct 1.

41.

Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.

Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, Cheung CS, Ho K, Chan AT.

Cancer Lett. 2014 Feb 1;343(1):24-32. doi: 10.1016/j.canlet.2013.09.007. Epub 2013 Sep 14.

PMID:
24041865
42.

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.

Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB, Chan AT.

Invest New Drugs. 2013 Dec;31(6):1399-408. doi: 10.1007/s10637-013-0007-z. Epub 2013 Aug 24.

PMID:
23975511
43.

Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.

Tsao A, Hui EP, Juergens R, Marur S, Huat TE, Cher GB, Hong RL, Hong WK, Chan AT.

Cancer Med. 2013 Jun;2(3):351-9. doi: 10.1002/cam4.79. Epub 2013 Apr 18.

44.

Re: roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial.

Chan SL, Hui EP, Yu S, Yeo W.

J Natl Cancer Inst. 2013 Apr 17;105(8):580. doi: 10.1093/jnci/djt047. Epub 2013 Mar 15. No abstract available.

PMID:
23503599
45.

Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.

Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT.

Cancer Res. 2013 Mar 15;73(6):1676-88. doi: 10.1158/0008-5472.CAN-12-2448. Epub 2013 Jan 24.

46.

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, Felip E; EHNS–ESMO–ESTRO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii83-5. No abstract available.

PMID:
22997460
47.

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.

Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Tsao SW, Li Y, Chan AT.

Invest New Drugs. 2013 Jun;31(3):567-75. doi: 10.1007/s10637-012-9896-5. Epub 2012 Nov 11.

PMID:
23143779
48.

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC.

J Clin Oncol. 2012 Sep 20;30(27):3361-7. doi: 10.1200/JCO.2011.41.2395. Epub 2012 Aug 20.

49.

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.

Ma BB, Lui VW, Cheung CS, Lau CP, Ho K, Hui EP, Tsui SK, Ng MH, Cheng SH, Ng PK, Tsao SW, Chan AT.

Invest New Drugs. 2013 Feb;31(1):30-8. doi: 10.1007/s10637-012-9828-4. Epub 2012 May 8.

PMID:
22565394
50.

Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT.

Radiother Oncol. 2012 Sep;104(3):300-4. doi: 10.1016/j.radonc.2011.12.022. Epub 2012 Jan 31.

PMID:
22300609

Supplemental Content

Support Center